The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs
Abstract
Osteoporosis and low bone mass are currently estimated to be a major public health risk affecting >50% of the female population over the age of 50. Because of their bone-selective pharmacokinetics, nitrogen-containing bisphosphonates (N-BPs), currently used as clinical inhibitors of bone-resorption diseases, target osteoclast farnesyl pyrophosphate synthase (FPPS) and inhibit protein prenylation. FPPS, a key branchpoint of the mevalonate pathway, catalyzes the successive condensation of isopentenyl pyrophosphate with dimethylallyl pyrophosphate and geranyl pyrophosphate. To understand the molecular events involved in inhibition of FPPS by N-BPs, we used protein crystallography, enzyme kinetics, and isothermal titration calorimetry. We report here high-resolution x-ray structures of the human enzyme in complexes with risedronate and zoledronate, two of the leading N-BPs in clinical use. These agents bind to the dimethylallyl/geranyl pyrophosphate ligand pocket and induce a conformational change. The interactions of the N-BP cyclic nitrogen with Thr-201 and Lys-200 suggest that these inhibitors achieve potency by positioning their nitrogen in the proposed carbocation-binding site. Kinetic analyses reveal that inhibition is competitive with geranyl pyrophosphate and is of a slow, tight binding character, indicating that isomerization of an initial enzyme–inhibitor complex occurs with inhibitor binding. Isothermal titration calorimetry indicates that binding of N-BPs to the apoenzyme is entropy-driven, presumably through desolvation entropy effects. These experiments reveal the molecular binding characteristics of an important pharmacological target and provide a route for further optimization of these important drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Self-citationLikelihood-enhanced fast rotation functions
Storoni, L. C., McCoy, A. J., & Read, R. J. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444903028956 · Cited by 1,172
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Self-citationThe Behavior and Significance of Slow‐Binding Enzyme Inhibitors
Morrison, J. F., & Walsh, C. T. (1988) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470123072.ch5 · Cited by 840
Bisphosphonates: from the laboratory to the clinic and back again
Russell, R. G. G., & Rogers, M. J. (1999) · Bone · doi:10.1016/s8756-3282(99)00116-7 · Cited by 840
Self-citationFisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G. G., Rodan, G. A., & Reszka, A. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.133 · Cited by 676
Self-citationNew Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Rogers, M. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033453640 · Cited by 579
Self-citationCrystal Structure of Recombinant Farnesyl Diphosphate Synthase at 2.6-.ANG. Resolution
Tarshis, L. C., Yan, M., Poulter, C. D., & Sacchettini, J. C. (1994) · Biochemistry · doi:10.1021/bi00202a004 · Cited by 424
Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate Synthase
Bergstrom, J. D., Bostedor, R. G., Masarachia, P. J., Reszka, A. A., & Rodan, G. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1502 · Cited by 402
Exact Analysis of Competition Ligand Binding by Displacement Isothermal Titration Calorimetry
Sigurskjold, B. W. (2000) · Analytical Biochemistry · doi:10.1006/abio.1999.4402 · Cited by 368
Regulation of product chain length by isoprenyl diphosphate synthases
Tarshis, L. C., Proteau, P. J., Kellogg, B. A., Sacchettini, J. C., & Poulter, C. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15018 · Cited by 346
Structural Basis for Bisphosphonate-mediated Inhibition of Isoprenoid Biosynthesis
Hosfield, D. J., Zhang, Y., Dougan, D. R., Broun, A., Tari, L. W., Swanson, R. V., & Finn, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300511200 · Cited by 272
Frith, J. C., M�nkk�nen, J., Auriola, S., M�nkk�nen, H., & Rogers, M. J. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200109)44:9<2201::aid-art374>3.0.co;2-e · Cited by 268
Self-citationVan Beek, E., Löwik, C., Van Der Pluijm, G., & Papapoulos, S. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.5.722 · Cited by 237
Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs
Rondeau, J., Bitsch, F., Bourgier, E., Geiser, M., Hemmig, R., Kroemer, M., Lehmann, S., Ramage, P., Rieffel, S., Strauss, A., et al. (2006) · ChemMedChem · doi:10.1002/cmdc.200500059 · Cited by 226
Bisphosphonate Mechanism of Action
Rodan, G., & Reszka, A. (2002) · Current Molecular Medicine · doi:10.2174/1566524023362104 · Cited by 195
van Beek, E., Pieterman, E., Cohen, L., Löwik, C., & Papapoulos, S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0224 · Cited by 195
Velázquez‐Campoy, A., Kiso, Y., & Freire, E. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2333 · Cited by 157
Martin, M., Arnold, W. D., Heath, H. T., Urbina, J. A., & Oldfield, E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1404 · Cited by 153
van Beek, E. R., Löwik, C. W. G. M., Ebetino, F. H., & Papapoulos, S. E. (1998) · Bone · doi:10.1016/s8756-3282(98)00120-3 · Cited by 125
Self-citationSanders, J. M., Gómez, A. O., Mao, J., Meints, G. A., Brussel, E. M. V., Burzynska, A. Z., Kafarski, P. K., González‐Pacanowska, D., & Oldfield, E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0302344 · Cited by 117
Thermodynamic dissection of the binding energetics of KNI‐272, a potent HIV‐1 protease inhibitor
Velázquez‐Campoy, A., Luque, I., Todd, M. J., Milutinovich, M., Kiso, Y., & Freire, E. (2000) · Protein Science · doi:10.1110/ps.9.9.1801 · Cited by 99
Copeland, R. A. (2000) · doi:10.1002/0471220639.ch9 · Cited by 57
Human liver prenyltransferase and its characterization
Barnard, G. F., & Popják, G. J. (1981) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(81)90086-3 · Cited by 56
Cited by
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Self-citationBisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Self-citationRemarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry
Mucha, A., Kafarski, P., & Berlicki, Ł. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200587f · Cited by 672
Molecular Mechanisms of Action of Bisphosphonates: Current Status
Roelofs, A. J., Thompson, K., Gordon, S., & Rogers, M. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0843 · Cited by 568
Self-citation
Metadata
- Authors
- Kavanagh, K. L., Guo, K., Dunford, J. E., Wu, X., Knapp, S., Ebetino, F. H., Rogers, M. J., Russell, R. G. G., & Oppermann, U.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-05-16
- Volume
- 103
- Issue
- 20
- Pages
- 7829-7834
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2124166505
- Cited by
- 536
- References
- 28
- FWCI
- 15.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.